Tumor organoids may be more suitable for clinical personalized chemotherapeutic drug screening in lung adenocarcinoma.

ABSTRACT:

Objective

The formulation of precision treatment strategies and the analysis of drug-resistance mechanisms for lung adenocarcinoma are highly dependent on in vitro models that can faithfully reflect tumor heterogeneity, dynamic drug responses, and tumor-stroma interactions. While existing preclinical models, such as two-dimensional (2D) adherent models and animal models, are widely used, their limitations in accurately recapitulating patient-specific microenvironments and the evolution of drug-resistant clones under chemotherapeutic pressure significantly restrict the reliability of treatment predictions.

Methods

The study utilized a three-dimensional (3D) organoid model, a 2D adherent model, and an animal model constructed from the A549 cell line to dynamically monit

SUBMITTER: Yun W 

PROVIDER: S-EPMC12528213 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature